Pharmaceuticals & Life Sciences

Knowledge Base Automation for Pharmaceuticals & Life Sciences

Knowledge Base Automation for pharmaceuticals & life sciences, built around the constraint that defines the sector: GxP validation means every system change needs documented evidence before it reaches production.

Regulations in scope
5
Systems we integrate
5
Typical first release
6 weeks

What changes when it is pharmaceuticals & life sciences

The best source for a runbook is what the system actually does, not what someone remembers it doing eighteen months ago.

In pharmaceuticals & life sciences, GxP validation means every system change needs documented evidence before it reaches production. That single fact reshapes how knowledge base automation has to be built here, the guardrails, the approval points and the evidence trail are design inputs rather than things bolted on before go-live.

The workload we are most often asked to take on first is batch record review, usually integrated against pharmacovigilance databases. Integration comes before intelligence. A model that cannot reach your systems of record is a demo with good manners.

Multi-model by default, so a provider outage is a routing decision rather than an incident. Six weeks to something running in production, not six quarters to a strategy document.

The sector constraints we design around

Defining constraint
GxP validation means every system change needs documented evidence before it reaches production
Regulations in scope
CDSCO · US FDA 21 CFR Part 11 · EU GMP Annex 11 · GxP validation · ICH guidelines
Systems of record
LIMS · QMS · eTMF · SAP · pharmacovigilance databases
Where we usually start
batch record review

Knowledge Base Automation workloads in pharmaceuticals & life sciences

  • batch record review
  • adverse event intake and coding
  • regulatory dossier assembly
  • deviation and CAPA drafting
  • literature monitoring

What is included

  • Ingestion from existing docs, tickets and chat history
  • Draft generation from actual system behaviour
  • Staleness detection with owner alerts
  • Search with citations across every source
  • Multilingual versions where teams need them
  • Review workflow so a human always approves

Questions from this sector

Can an AI system be GxP validated?

Yes, with a documented validation approach, IQ/OQ/PQ, defined intended use, change control and evidence of consistent performance. We build the validation pack alongside the system, not afterwards.

How do you handle 21 CFR Part 11?

Audit trails, electronic signatures, access control and record integrity designed in from the start, because retrofitting them is effectively a rebuild.

Will it replace our technical writers?

No. It removes the drudgery of first drafts and staleness tracking so writers spend their time on structure, accuracy and the hard explanations.

How does it know when content is stale?

By watching the underlying systems and code for changes that contradict what a document asserts, then alerting the document's owner.

Can it work across languages?

Yes, with human review on each language version rather than publishing machine translation unchecked.

Knowledge Base Automation for pharmaceuticals & life sciences, worth a conversation?

Tell us the workload and the regulation it sits under. We will tell you what is realistic.

Or email bd@dtrasglobal.com · call +91 74118 77878